CAJ | 학술논문

难辨梭菌感染（Clostridium dififcile infection, CDI）发病率正在升高，在有些国家已成为医院获得性感染主要致病菌之一。经典药物治疗是采用万古霉素和/或甲硝唑治疗，但近年随着甲硝唑耐药新突变株出现，临床对其处理日益困惑。2011年1月非达霉素获美国食品和药物管理局批准上市，为本病治疗开辟了新的治疗途径。本文就非达霉素药效学、药动学、安全性、药物相互作用以及临床应用进行了综合介绍，并对比了非达霉素与万古霉素在治疗CDI时药理作用等区别，供临床应用时参考。
난변사균감염（Clostridium dififcile infection, CDI）발병솔정재승고，재유사국가이성위의원획득성감염주요치병균지일。경전약물치료시채용만고매소화/혹갑초서치료，단근년수착갑초서내약신돌변주출현，림상대기처리일익곤혹。2011년1월비체매소획미국식품화약물관리국비준상시，위본병치료개벽료신적치료도경。본문취비체매소약효학、약동학、안전성、약물상호작용이급림상응용진행료종합개소，병대비료비체매소여만고매소재치료CDI시약리작용등구별，공림상응용시삼고。
The morbidity associated with Clostridium dififcile infection (CDI) is rising. In some countries, CDI has become one of the major pathogenic bacteria resulting in the hospital acquired infection. The classical drug therapy for CDI is the use of vancomycin and/or metronidazole. However, with emergence of the new metronidazole resistance mutants of Clostridium dififcile, the clinical treatments become progressively confused. The new therapeutic approach for CDI could not be effective till ifdaxomicin was approved by FDA in January 2011. This paper introduces the pharmacodynamics, pharmacokinetics, safety, drug interactions and clinical application of ifdaxomicin, and the pharmacological differences between ifdaxomicin and vancomycin in the treatment of CDI are compared so as to provide a reference for clinical application.